Biopharmaceutical company OKYO Pharma (NASDAQ:OKYO) has made an investigational new drug application for OK-101 with the U.S. Food and Drug Administration.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
OK-101 is being developed for the treatment of dry eye disease (DED). The company plans to commence a Phase 2 trial in DED in Q1 2023.
Further, the company is designating primary and secondary endpoints in the first-in-human study which could mean an accelerated timeline toward a new drug application for the drug.
OK-101 has demonstrated anti-inflammatory and neuropathic pain-reducing activities in mouse models and corneal neuropathic pain, respectively.
Read full Disclosure
